Related Experiment Videos
Oral acetylsalicylic acid (aspirin) challenge in asthmatic children
Insights
Acetylsalicylic acid (Aspirin) challenge in asthmatic children unexpectedly increased peak expiratory flow rate (PEFR). This significant finding suggests a novel response to aspirin in pediatric asthma patients.
Area of Science:
- Pediatric Allergy and Immunology
- Respiratory Medicine
- Pharmacology
Background:
- Asthma is a common chronic respiratory disease in children.
- Acetylsalicylic acid (Aspirin) is a widely used nonsteroidal anti-inflammatory drug.
- The effect of Aspirin on respiratory function in asthmatic children is not fully understood.
Purpose of the Study:
- To investigate the effect of oral acetylsalicylic acid (Aspirin) challenge on peak expiratory flow rate (PEFR) in children with asthma.
- To analyze the statistical significance of observed changes in PEFR following Aspirin administration.
Main Methods:
- Thirty-two asthmatic children (mean age 9.6 years) underwent oral Aspirin challenge.
- Peak expiratory flow rate (PEFR) was measured at 30-minute intervals for 3 hours post-challenge.
- Statistical analysis using Kolmogorov-Smirnov, Student's, and Wilcoxon tests was performed.
Main Results:
- A significant increase in PEFR values (13.9%) was observed 150 minutes after Aspirin challenge in the overall group (P = 0.001).
- A small, non-significant fall in PEFR (<8%) was noted in only three children.
- The majority of participants had a history of allergic symptoms and family atopy.
Conclusions:
- Oral acetylsalicylic acid (Aspirin) challenge can lead to a significant increase in peak expiratory flow rate (PEFR) in asthmatic children.
- This paradoxical response may be linked to mechanisms such as prostaglandin synthetase inhibition by Aspirin.
- Further research is warranted to elucidate the underlying mechanisms of this Aspirin-induced bronchodilation in pediatric asthma.
Abstract:
Thirty-two asthmatic children, mean age 9.6 years (range: 6-14 years), were studied by oral challenge with acetylsalicylic acid (Aspirin), and their PEFR was recorded at 30 min intervals for 3 hr. They had been asthmatic for a mean of 7.1 years. Other allergic symptoms (urticaria, rhinitis or atopic dermatitis), were present in 81% of the patients, and a family history of atopy in 94%; the mean blood eosinophilia was 590 cells per mm3. In three children aspirin induced a fall in PEFR values less than 8% which was non-significant. In the group as a whole there was an increase in the PEFR values of 13.9%, 150 min after aspirin challenge. These values where subjected to statistical analysis (Kolmogorov-Smirnov, Student's and Wilcoxon tests), which showed this increase to be significant at a level of P = 0.001. Possible mechanisms involving prostaglandin synthetase inhibition by aspirin are discussed as an explanation for this increase.